Conditioned media from cell lines: A complementary model to clinical specimens for the discovery of disease-specific biomarkers

Proteomics

Volumn 11, Issue 4, 2011, Pages 794-804

  Dowling, Paul ^a   Clynes, Martin ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Biomarkers; Biomedicine; Cell culture; Conditioned media; Secretome

Indexed keywords

ADIPONECTIN; ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; BIOLOGICAL MARKER; CATHEPSIN D; CD9 ANTIGEN; COMPLEMENT; CXCL16 CHEMOKINE; CYSTATIN C; FOLLISTATIN; GALECTIN 3 BINDING PROTEIN; GLUCOSE REGULATED PROTEIN 78; GROWTH DIFFERENTIATION FACTOR 15; HAPTOGLOBIN; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; PENTRAXIN 3; PERIPHERIN; PREALBUMIN; RESISTIN; SECRETOGRANIN II; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIMENTIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL INVASION; DEGENERATIVE DISEASE; DIABETES MELLITUS; EXTRACELLULAR MATRIX; HELA CELL; HUMAN; HUNTINGTON CHOREA; INSULIN RELEASE; LUNG ADENOCARCINOMA; MACHADO JOSEPH DISEASE; MASS SPECTROMETRY; NASOPHARYNX CARCINOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE; CULTURE MEDIA, CONDITIONED; HUMANS; MODELS, BIOLOGICAL; PROTEOME; PROTEOMICS;

EID: 79551493048     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000530     Document Type: Review

References (79)

1. Yamori, T., Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother. Pharmacol. 2003, 52, S74-S79.
2. Dowling, P., Meleady, P., Dowd, A., Henry, M. et al., Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim. Biophys. Acta 2007, 1774, 93-101.
3. Xue, H., Lu, B., Lai, M., The cancer secretome: a reservoir of biomarkers. J. Transl. Med. 2008, 6, 52.
4. Righetti, P. G., Castagna, A., Antonucci, F., Piubelli, C. et al., The proteome: anno Domini 2002. Clin. Chem. Lab. Med. 2003, 41, 425-438.
5. Zhong, L., Roybal, J., Chaerkady, R., Zhang, W. et al., Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res. 2008, 68, 7237-7245.
6. Volmer, M. W., Stuhler, K., Zapatka, M., Schoneck, A. et al., Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5, 2587-2601.
7. Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R. et al., Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5, 157-171.
8. Weiss, J. V., Klein-Scory, S., Kubler, S., Reinacher-Schick, A. et al., Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP. Int. J. Cancer. 2010. Epub ahead of print.
9. Klee, E. W., Sosa, C. P., Computational classification of classically secreted proteins. Drug Discov. Today 2007, 12, 234-240.
10. Nickel, W., Pathways of unconventional protein secretion. Curr. Opin. Biotechnol. 2010, 5, 621-626.
11. Andre, F., Schartz, N. E., Movassagh, M., Flament, C. et al., Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360, 295-305.
12. Zhou, M., Lucas, D. A., Chan, K. C., Issaq, H. J. et al., An investigation into the human serum "interactome". Electrophoresis 2004, 25, 1289-1298.
13. Ayache, S., Panelli, M., Marincola, F. M., Stroncek, D. F., Effects of storage time and exogenous protease inhibitors on plasma protein levels. Am. J. Clin. Pathol. 2006, 126, 174-184.
14. Gunawardana, C. G., Kuk, C., Smith, C. R., Batruch, I. et al., Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J. Proteome Res. 2009, 8, 4705-4713.
15. Kulasingam, V., Diamandis, E. P., Tissue culture-based breast cancer biomarker discovery platform. Int. J. Cancer 2008, 123, 2007-2012.
16. Martin, D. B, Gifford, D. R, Wright, M. E., Keller, A. et al., Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res. 2004, 64, 347-355.
17. Wong, S. C., Chan, C. M., Ma, B. B., Lam, M. Y. et al., Advanced proteomic technologies for cancer biomarker discovery. Expert Rev. Proteomics 2009, 6, 123-134.
18. Pellitteri-Hahn, M. C., Warren, M. C., Didier, D. N., Winkler, E. L. et al., Improved mass spectrometric proteomic profiling of the secretome of rat vascular endothelial cells. J. Proteome Res. 2006, 5, 2861-2864.
19. Srisomsap, C., Sawangareetrakul, P., Subhasitanont, P., Chokchaichamnankit, D. et al., Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J. Biomed. Biotechnol. 2010, 2010, 437143.
20. Higa, L. M., Caruso, M. B., Canellas, F., Soares, M. R. et al., Secretome of HepG2 cells infected with dengue virus: implications for pathogenesis. Biochim. Biophys. Acta 2008, 1784, 1607-1616.
21. Mbeunkui, F., Fodstad, O., Pannell, L. K., Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2-D LC-MS/MS. J. Proteome Res. 2006, 5, 899-906.
22. Weng, L. P., Wu, C. C., Hsu, B. L., Chi, L. M. et al., Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J. Proteome Res. 2008, 7, 3765-3775.
23. Zwickl, H., Traxler, E., Staettner, S., Parzefall, W. et al., A novel technique to specifically analyze the secretome of cells and tissues. Electrophoresis 2005, 26, 2779-2785.
24. Gundacker, N. C., Haudek, V. J., Wimmer, H., Slany, A. et al., Cytoplasmic proteome and secretome profiles of differently stimulated human dendritic cells. J Proteome Res. 2009, 8, 2799-2811.
25. Colzani, M., Waridel, P., Laurent, J., Faes, E. et al., Metabolic labeling and protein linearization technology allow the study of proteins secreted by cultured cells in serum-containing media. J. Proteome Res. 2009, 8, 4779-4788.
26. Jiang, L., He, L., Fountoulakis, M., Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. J. Chromatogr. A 2004, 1023, 317-320.
27. Chang, K. P., Wu, C. C., Chen, H. C., Chen, S. J. et al., Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 2010, 10, 2644-2660.
28. Slany, A., Haudek, V. J., Zwickl, H., Gundacker, N. C. et al., Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J. Proteome Res. 2010, 9, 6-21.
29. Mathias, R. A., Wang, B., Ji, H., Kapp, E. A. et al., Secretome-based proteomic profiling of Ras-transformed MDCK cells reveals extracellular modulators of epithelial-mesenchymal transition. J. Proteome Res. 2009, 8, 2827-2837.
30. Currid, C. A., O'Connor, D. P., Chang, B. D., Gebus, C. et al., Proteomic analysis of factors released from p21-overexpressing tumour cells. Proteomics 2006, 6, 3739-3753.
31. Baggetta, R., De Andrea, M., Gariano, G. R., Mondini, M. et al., The interferon-inducible gene IFI16 secretome of endothelial cells drives the early steps of the inflammatory response. Eur. J. Immunol. 2010, 40, 2182-2189.
32. Chenau, J., Michelland, S., de Fraipont, F., Josserand, V. et al., The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J. Proteome Res. 2009, 8, 4579-4591.
33. Mauri, P., Scarpa, A., Nascimbeni, A. C., Benazzi, L. et al., Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J. 2005, 19, 1125-1127.
34. Kashyap, M. K., Harsha, H. C., Renuse, S., Pawar, H. et al., SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol. Ther. 2010, 8, 796-810.
35. Xu, B. J., Yan, W., Jovanovic, B., An, A. Q. et al., Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts. Proteomics 2010 10 2458-2470.
36. Gao, B. B., Stuart, L., Feener, E. P., Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome: application on angiotensin II-stimulated smooth muscle cells secretome. Mol. Cell. Proteomics 2008, 7, 2399-2409.
37. Schiarea, S., Solinas, G., Allavena, P., Scigliuolo, G. M. et al., Secretome analysis of multiple pancreatic cancer cell lines reveals perturbations of key functional networks. J. Proteome Res. 2010, 9, 4376-4392.
38. Taylor, C. R., Levenson, R. M., Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006, 49, 411-424.
39. Choi, S., Kim, J., Yea, K., Suh, P. G. et al., Targeted label-free quantitative analysis of secretory proteins from adipocytes in response to oxidative stress. Anal. Biochem. 2010, 401, 196-202.
40. Whiteaker, J. R., Zhao, L., Anderson, L., Paulovich, A. G., An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 2010, 9, 184-196.
41. Zimmet, P., Alberti, K. G., Shaw, J., Global and societal implications of the diabetes epidemic. Nature 2001, 414, 782-787.
42. Stumvoll, M., Goldstein, B. J., van Haeften, T. W., Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365, 1333-1346.
43. Mlinar, B., Marc, J., Janez, A., Pfeifer, M., Molecular mechanisms of insulin resistance and associated diseases. Clin. Chim. Acta 2007, 375, 20-35.
44. Mohamadi, A., Cooke, D. W., Type 2 diabetes mellitus in children and adolescents. Adolesc. Med. State Art Rev. 2010, 21, 103-119.
45. Rittig, K., Hieronimus, A., Thamer, C., Machann, J. et al., Reducing visceral adipose tissue mass is essential for improving endothelial function in type 2 diabetes prone individuals. Atherosclerosis. 2010, 2, 575-579.
46. Breitling, R., Robust signaling networks of the adipose secretome. Trends Endocrinol. Metab. 2009, 20, 1-7.
47. Zvonic, S., Lefevre, M., Kilroy, G., Floyd, Z. E. et al., Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol. Cell. Proteomics 2007, 6, 18-28.
48. Zhou, H., Xiao, Y., Li, R., Hong, S. et al., Quantitative analysis of secretome from adipocytes regulated by insulin. Acta Biochim. Biophys. Sin. (Shanghai) 2009, 41, 910-921.
49. Dowling, P., Shields, W., Rani, S., Meleady, P. et al., Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction. Electrophoresis 2008, 29, 4141-4149.
50. Song, G., Cui, Y., Zhong, N., Han, J., Proteomic characterisation of pancreatic islet beta-cells stimulated with pancreatic carcinoma cell conditioned medium. J. Clin. Pathol. 2009, 62, 802-807.
51. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 2010, 5, 277-300.
52. Griffith, O. L., Chiu, C. G., Gown, A. M., Jones, S. J., Wiseman, S. M., Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev. Anticancer Ther. 2008, 8, 1399-1413.
53. Patz, E. F., Jr., Campa, M. J., Gottlin, E. B., Kusmartseva, I. et al., Panel of serum biomarkers for the diagnosis of lung cancer. J. Clin. Oncol. 2007, 25, 5578-5583.
54. Matsumoto, T., Kawashima, Y., Nagashio, R., Kageyama, T. et al., A new possible lung cancer marker: VGF detection from the conditioned medium of pulmonary large cell neuroendocrine carcinoma-derived cells using secretome analysis. Int. J. Biol. Markers 2009, 24, 282-285.
55. Arango, B. A., Castrellon, A. B., Perez, C. A., Raez, L. E., Santos, E. S., Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert Rev. Anticancer Ther. 2010, 10, 377-386.
56. Chang, Y. H., Wu, C. C., Chang, K. P., Yu, J. S. et al., Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. J. Proteome Res. 2009, 8, 5465-5474.
57. Wang, C. L., Wang, C. I., Liao, P. C., Chen, C. D. et al., Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J. Proteome Res. 2009, 8, 4428-4440.
58. Mbeunkui, F., Metge, B. J., Shevde, L. A., Pannell, L. K., Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J. Proteome Res. 2007, 6, 2993-3002.
59. Xue, H., Lu, B., Zhang, J., Wu, M. et al., Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J. Proteome Res. 2010, 9, 545-555.
60. Sardana, G., Jung, K., Stephan, C., Diamandis, E. P., Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 2008, 7, 3329-3338.
61. Kulasingam, V., Diamandis, E. P., Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol. Cell. Proteomics 2007, 6, 1997-2011.
62. Lahat, G., Zhu, Q. S., Huang, K. L., Wang, S. et al., Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010, 5, e10105.
63. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., Evans, D. A., Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60, 1119-1122.
64. Wancata, J., Musalek, M., Alexandrowicz, R., Krautgartner, M., Number of dementia sufferers in Europe between the years 2000 and 2050. Eur. Psychiatry 2003, 18, 306-313.
65. Liu, B., Hong, J. S., Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304, 1-7.
66. Agostinho, P., Cunha, R. A., Oliveira, C., Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 2010, 25, 2766-2778.
67. Tansey, M. G., Goldberg, M. S., Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37, 510-518.
68. Suk, K., Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers. Expert Rev. Proteomics 2010, 7, 263-274.
69. Kim, S., Ock, J., Kim, A. K., Lee, H. W. et al., Neurotoxicity of microglial cathepsin D revealed by secretome analysis. J. Neurochem. 2007, 103, 2640-2650.
70. Jeon, H., Lee, S., Lee, W. H., Suk, K., Analysis of glial secretome: the long pentraxin PTX3 modulates phagocytic activity of microglia. J. Neuroimmunol. 2010, 1-2, 63-72.
71. Hur, J., Lee, P., Kim, M. J., Kim, Y., Cho, Y. W., Ischemia-activated microglia induces neuronal injury via activation of gp91phox NADPH oxidase. Biochem. Biophys. Res. Commun. 2010, 391, 1526-1530.
72. Marusyk, A., Polyak, K., Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 2010, 1805, 105-117.
73. Ween, M. P., Lokman, N. A., Hoffmann, P., Rodgers, R. J. et al., Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int. J. Cancer. 2010, Epub ahead of print.
74. Wu, H. Y., Chang, Y. H., Chang, Y. C., Liao, P. C., Proteomics analysis of nasopharyngeal carcinoma cell secretome using a hollow fiber culture system and mass spectrometry. J. Proteome Res. 2009, 8, 380-389.
75. Lipman, N. S., Jackson, L. R., Hollow fibre bioreactors: an alternative to murine ascites for small scale (<1 gram) monoclonal antibody production. Res. Immunol. 1998, 149, 571-576.
76. Cabrera, C. M., Cobo, F., Nieto, A., Cortes, J. L. et al., Identity tests: determination of cell line cross-contamination. Cytotechnology 2006, 51, 45-50.
77. Buehring, G. C., Eby, E. A., Eby, M. J., Cell line cross-contamination: how aware are Mammalian cell culturists of the problem and how to monitor it? In Vitro Cell. Dev. Biol. Anim. 2004, 40, 211-215.
78. Jesneck, J. L., Mukherjee, S., Yurkovetsky, Z., Clyde, M. et al., Do serum biomarkers really measure breast cancer? Biomed. Chromatogr. Cancer 2009, 9, 164.
79. Foster, C. S., Cooper, C. S., Urgent need to develop independent biomarkers for functional, diagnostic and prognostic application in oncology research. Biomarkers Med. 2009, 3, 329-333.